Skip to main content

Advertisement

Table 3 10-year average cost, number of exacerbations, and quality adjusted life-years for each intervention using both pairwise meta-analysis (PMA) and network meta-analysis (NMA)

From: The impact of incorporating Bayesian network meta-analysis in cost-effectiveness analysis - a case study of pharmacotherapies for moderate to severe COPD

Intervention Meta-analysis Costs ($) Number of exacerbations Quality adjusted life years (QALYs)
Placebo PMA 25 458 (19 927, 32 312) 12.6 (12.5, 12.8) 5.67 (5.36, 5.99)
NMA 25 316 (19 950, 31 897) 12.6 (12.5, 12.7) 5.67 (5.34, 5.99)
ICS PMA 27 116 (22 194, 33 307) 10.3 (8.62, 11.9) 5.73 (5.40, 6.07)
NMA 26 979 (21 991, 33 420) 10.2 (9.10, 11.4) 5.73 (5.38, 6.06)
LABA PMA 28 304 (23 081, 34 897) 11.0 (9.31, 13.2) 5.71 (5.39, 6.04)
NMA 28 116 (23 002, 34 604) 10.9 (9.86, 12.2) 5.71 (5.37, 6.05)
ICS + LABA PMA 30 849 (25 947, 36 741) 9.13 (7.69, 11.2) 5.76 (5.42, 6.10)
NMA 30 496 (25 902, 36 133) 8.85 (7.83, 10.0) 5.75 (5.40, 6.11)
LAMA PMA 28 840 (23 928, 35 073) 9.33 (7.47, 11.4) 5.76 (5.42, 6.10)
NMA 28 816 (24 237, 34 548) 9.39 (8.37, 10.4) 5.77 (5.41, 6.12)